You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Met EGFR bispecific

Showing 1 - 25 of 3,669
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

Not yet recruiting
  • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
  • MCLA-129: 1500mg or 2000mg IV Q2W
  • Befotertinib: 75 mg or 100 mg Po QD
  • Bengbu, Anhui, China
  • +2 more
Aug 28, 2023

Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • Amivantamab
  • +3 more
  • (no location specified)
Oct 30, 2023

NSCLC Metastatic, Gastric Cancer, Head Neck Cancer Trial in Orange, West Valley City (MCLA-129)

Recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • +2 more
  • Orange, California
  • +1 more
May 21, 2021

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Gastric Cancer Trial in Goyang (CKD-702 in combination with irinotecan)

Recruiting
  • Gastric Cancer
  • CKD-702 in combination with irinotecan
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Feb 20, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

Completed
  • Colorectal Cancer Metastatic
  • C-met Overexpression
  • Tivantinib (ARQ197)
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
Sep 8, 2022

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Lung Cancer Trial (Savolitinib, Durvalumab)

Recruiting
  • Lung Cancer
  • Beijing, China
  • +2 more
Jan 11, 2023

Locally Advanced or Metastatic Solid Tumors, Squamous-cell NSCLC Trial in Shanghai, Xuzhou (HLX35)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Squamous-cell Non-small Cell Lung Cancer
  • Shanghai, China
  • +1 more
Jun 28, 2022

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Charlottesville (EGFR BATs after

Recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • EGFR BATs after standard of care chemo
  • Charlottesville, Virginia
    University of Virginia
Mar 30, 2022

Locally Advanced or Metastatic Epithelial Tumor Trial in Guangzhou (SI-B001)

Active, not recruiting
  • Locally Advanced or Metastatic Epithelial Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 14, 2022

Solid Tumor, NSCLC, Head Neck Cancer Trial in China (MCLA-129)

Recruiting
  • Solid Tumor
  • +3 more
  • Baoding, China
  • +63 more
Dec 19, 2021

Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in New York, Charlottesville

Active, not recruiting
  • Pancreatic Cancer
  • +3 more
  • anti-EGFR-bispecific antibody armed activated T-cells
  • New York, New York
  • +1 more
Oct 7, 2021

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC Trial in Guangzhou (Osimertinib, Savolitinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong General Hospital, Gua
Dec 6, 2021

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Nov 30, 2022

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

c-MET Expression and EGFR Gene Mutation Correlation With

Completed
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Recurrent
    • Hwasun, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    Esophagogastric Cancer Trial in United States (Amivantamab)

    Recruiting
    • Esophagogastric Cancer
    • Boston, Massachusetts
    • +7 more
    Oct 24, 2022

    Solid Tumor, Adult Trial (HLX35, HLX10)

    Not yet recruiting
    • Solid Tumor, Adult
    • (no location specified)
    Jun 29, 2022

    NSCLC, Solid Tumor Trial in Tianjin (HS-20117)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Solid Tumor
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Jul 10, 2023

    Non-Small-Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

    Recruiting
    • Non-Small-Cell Lung Cancer
    • Duarte, California
    • +100 more
    Jan 31, 2023

    NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

    Completed
    Has Results
    • Non-small Cell Lung Cancer
    • Beijing, China
    • +43 more
    Oct 13, 2022